Capricor Therapeutics, Inc. (CAPR) vs DiaMedica Therapeutics, Inc. (DMAC)

Capricor Therapeutics, Inc. and DiaMedica Therapeutics, Inc. are both Biotechnology companies. Capricor Therapeutics, Inc. and DiaMedica Therapeutics, Inc. are of similar size ($455.2M and $449.2M). Across the 10 metrics below, Capricor Therapeutics, Inc. leads on 6 and DiaMedica Therapeutics, Inc. on 4.

Valuation

Metric CAPR DMAC Biotechnology median
P/E n/m n/m 8.56
P/S 19.43 n/m 10.17
P/B 1.76 11.58 2.34
Price to free cash flow 3.31 n/m 20.42
EV/EBITDA n/m n/m 0.69
EV/Sales 9.38 n/m 9.64
Earnings yield (32.80%) (8.74%) (29.41%)
Free cash flow yield 30.25% (7.10%) (23.50%)

Profitability

Metric CAPR DMAC Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (73.70%) (114.62%) (56.66%)
Return on assets (51.53%) (98.18%) (49.22%)
Return on invested capital (1,019.73%) 0.00% 0.00%

Growth

Metric CAPR DMAC Biotechnology median
Revenue growth (TTM) (11.55%) — 5.64%
EPS growth (last fiscal year) (96.52%) (16.67%) 30.08%
Revenue growth, 5-year CAGR 85.83% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CAPR DMAC Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.35 6.72 4.72
Net debt to EBITDA 2.99 1.70 0.96

Dividend

Metric CAPR DMAC Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric CAPR DMAC Biotechnology median
Market cap 455.23m 449.20m 151.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack